Natural killer T cells and mucosal-associated invariant T cells in lung infections

Frontiers in Immunology

Volumn 9, Issue AUG, 2018, Pages

  Trottein, François ^a,b,c,d,e   Paget, Christophe ^f,g  

^a UNIV LILLE   (France)

^b CNRS   (France)

^c INSERM U1019   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e INSTITUT PASTEUR DE LILLE   (France)

^f INSERM   (France)

^g UNIVERSITÉ DE TOURS   (France)

Author keywords

Bacteria; Immunotherapy; Infection; Lung; Mucosal immunity; Mucosal associated invariant T cells; Natural killer T cells; Viruses

Indexed keywords

CD1D ANTIGEN; EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR; CD1D PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MINOR HISTOCOMPATIBILITY ANTIGEN; MR1 PROTEIN, HUMAN; VACCINE;

CYTOKINE RELEASE; FRANCISELLA TULARENSIS; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFLUENZA A VIRUS; LUNG INFECTION; MUCOSAL IMMUNITY; MUCOSAL-ASSOCIATED INVARIANT T CELL; NATURAL KILLER T CELL; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIAE; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BACTERIAL PNEUMONIA; IMMUNOLOGY; INNATE IMMUNITY; LUNG TUBERCULOSIS; VIRUS PNEUMONIA;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD1D; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; MINOR HISTOCOMPATIBILITY ANTIGENS; MUCOSAL-ASSOCIATED INVARIANT T CELLS; NATURAL KILLER T-CELLS; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; TUBERCULOSIS, PULMONARY; VACCINES;

EID: 85051130497     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01750     Document Type: Review

References (218)

1. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science (1995) 268:863-5. doi:10.1126/science.7538697
2. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J Exp Med (1994) 180:1097-106. doi:10.1084/jem.180.3.1097
3. Michel M-L, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med (2007) 204:995-1001. doi:10.1084/jem.20061551
4. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc Natl Acad Sci U S A (2008) 105:11287-92. doi:10.1073/pnas.0801631105
5. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol (2010) 11:197-206. doi:10.1038/ni.1841
6. Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol (2012) 12:845-57. doi:10.1038/nri3328
7. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol (2007) 25:297-336. doi:10.1146/annurev.immunol.25.022106.141711
8. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol (2015) 16:1114-23. doi:10.1038/ni.3298
9. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 278:1626-9. doi:10.1126/science.278.5343.1626
10. Zajonc DM, Girardi E. Recognition of microbial glycolipids by natural killer T cells. Front Immunol (2015) 6:400. doi:10.3389/fimmu.2015.00400
11. Van Kaer L, Parekh VV, Wu L. The response of CD1d-restricted invariant NKT cells to microbial pathogens and their products. Front Immunol (2015) 6:226. doi:10.3389/fimmu.2015.00226
12. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol (2007) 5:405-17. doi:10.1038/nrmicro1657
13. Doisne J-M, Soulard V, Bécourt C, Amniai L, Henrot P, Havenar-Daughton C, et al. Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1-invariant NKT cells to bacteria. J Immunol (2011) 186:662-6. doi:10.4049/jimmunol.1002725
14. Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KCF, et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity (2007) 27:597-609. doi:10.1016/j.immuni.2007.08.017
15. Tyznik AJ, Verma S, Wang Q, Kronenberg M, Benedict CA. Distinct requirements for activation of NKT and NK cells during viral infection. J Immunol (2014) 192:3676-85. doi:10.4049/jimmunol.1300837
16. Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol (2009) 39:1893-901. doi:10.1002/eji.200939349
17. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol (2013) 14:1146-54. doi:10.1038/ni.2731
18. Engel I, Seumois G, Chavez L, Samaniego-Castruita D, White B, Chawla A, et al. Innate-like functions of natural killer T cell subsets result from highly divergent gene programs. Nat Immunol (2016) 17:728-39. doi:10.1038/ni.3437
19. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol (2008) 20:358-68. doi:10.1016/j.coi.2008.03.018
20. Stober D, Jomantaite I, Schirmbeck R, Reimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol (2003) 170:2540-8. doi:10.4049/jimmunol.170.5.2540
21. Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ. Role of γδ T cells in α-galactosylceramide-mediated immunity. J Immunol (2012) 188:3928-39. doi:10.4049/jimmunol.1103582
22. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol (2010) 11:1039-46. doi:10.1038/ni.1942
23. Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol (1999) 163:2373-7
24. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 163:4647-50
25. Nieuwenhuis EES, Matsumoto T, Exley M, Schleipman RA, Glickman J, Bailey DT, et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med (2002) 8:588-93. doi:10.1038/nm0602-588
26. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 104:3984-9. doi:10.1073/pnas.0700191104
27. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 171:5140-7. doi:10.4049/jimmunol.171.10.5140
28. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med (1999) 189:1121-8. doi:10.1084/jem.189.7.1121
29. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol (2001) 167:3114-22. doi:10.4049/jimmunol.167.6.3114
30. Macho Fernandez E, Chang J, Fontaine J, Bialecki E, Rodriguez F, Werkmeister E, et al. Activation of invariant natural killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. Int J Pharm (2012) 423:45-54. doi:10.1016/j.ijpharm.2011.04.068
31. Dhodapkar MV, Kumar V. Type II NKT cells and their emerging role in health and disease. J Immunol (2017) 198:1015-21. doi:10.4049/jimmunol.1601399
32. Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, et al. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol (2001) 167:5531-4. doi:10.4049/jimmunol.167.10.5531
33. Van Rhijn I, Young DC, Im JS, Levery SB, Illarionov PA, Besra GS, et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci U S A (2004) 101:13578-83. doi:10.1073/pnas.0402838101
34. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, Mallevaey T, et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol (2012) 13:857-63. doi:10.1038/ni.2372
35. Tatituri RVV, Watts GFM, Bhowruth V, Barton N, Rothchild A, Hsu F-F, et al. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc Natl Acad Sci U S A (2013) 110:1827-32. doi:10.1073/pnas.1220601110
36. Arrenberg P, Halder R, Dai Y, Maricic I, Kumar V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci U S A (2010) 107:10984-9. doi:10.1073/pnas.1000576107
37. Maricic I, Girardi E, Zajonc DM, Kumar V. Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. J Immunol (2014) 193:4580-9. doi:10.4049/jimmunol.1400699
38. Girardi E, Maricic I, Wang J, Mac T-T, Iyer P, Kumar V, et al. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat Immunol (2012) 13:851-6. doi:10.1038/ni.2371
39. Koay H-F, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol (2016) 17:1300-11. doi:10.1038/ni.3565
40. Bedel R, Matsuda JL, Brigl M, White J, Kappler J, Marrack P, et al. Lower TCR repertoire diversity in Traj18-deficient mice. Nat Immunol (2012) 13:705-6. doi:10.1038/ni.2347
41. Zhang J, Bedel R, Krovi SH, Tuttle KD, Zhang B, Gross J, et al. Mutation of the Traj18 gene segment using TALENs to generate natural killer T cell deficient mice. Sci Rep (2016) 6:27375. doi:10.1038/srep27375
42. Chandra S, Zhao M, Budelsky A, de Mingo Pulido A, Day J, Fu Z, et al. A new mouse strain for the analysis of invariant NKT cell function. Nat Immunol (2015) 16:799-800. doi:10.1038/ni.3203
43. Dasgupta S, Kumar V. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset. Immunogenetics (2016) 68:665-76. doi:10.1007/s00251-016-0930-1
44. Macho-Fernandez E, Brigl M. The extended family of CD1d-restricted NKT cells: sifting through a mixed bag of TCRs, antigens, and functions. Front Immunol (2015) 6:362. doi:10.3389/fimmu.2015.00362
45. Pellicci DG, Uldrich AP. Unappreciated diversity within the pool of CD1d-restricted T cells. Semin Cell Dev Biol (2017). doi:10.1016/j.semcdb.2017.11.031
46. Uldrich AP, Patel O, Cameron G, Pellicci DG, Day EB, Sullivan LC, et al. A semi-invariant Va10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol (2011) 12:616-23. doi:10.1038/ni.2051
47. Le Nours J, Praveena T, Pellicci DG, Gherardin NA, Ross FJ, Lim RT, et al. Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens. Nat Commun (2016) 7:10570. doi:10.1038/ncomms10570
48. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, et al. The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vd1 TCR. Eur J Immunol (2012) 42:2505-10. doi:10.1002/eji.201242531
49. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the γδ TCR. Nat Immunol (2013) 14:1137-45. doi:10.1038/ni.2713
50. Luoma AM, Castro CD, Mayassi T, Bembinster LA, Bai L, Picard D, et al. Crystal structure of Vd1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells. Immunity (2013) 39:1032-42. doi:10.1016/j.immuni.2013.11.001
51. Russano AM, Agea E, Corazzi L, Postle AD, De Libero G, Porcelli S, et al. Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted gamma delta T cells. J Allergy Clin Immunol (2006) 117:1178-84. doi:10.1016/j.jaci.2006.01.001
52. Dieudé M, Striegl H, Tyznik AJ, Wang J, Behar SM, Piccirillo CA, et al. Cardiolipin binds to CD1d and stimulates CD1d-restricted γδ T cells in the normal murine repertoire. J Immunol (2011) 186:4771-81. doi:10.4049/jimmunol.1000921
53. Pellicci DG, Uldrich AP, Le Nours J, Ross F, Chabrol E, Eckle SBG, et al. The molecular bases of δ/αβ T cell-mediated antigen recognition. J Exp Med (2014) 211:2599-615. doi:10.1084/jem.20141764
54. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature (2003) 422:164-9. doi:10.1038/nature01433
55. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med (1999) 189:1907-21. doi:10.1084/jem.189.12.1907
56. Tang X-Z, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol (2013) 190:3142-52. doi:10.4049/jimmunol.1203218
57. Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood (2011) 117:1250-9. doi:10.1182/blood-2010-08-303339
58. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med (2013) 210:2305-20. doi:10.1084/jem.20130958
59. Eckle SBG, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HEG, Reantragoon R, et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J Exp Med (2014) 211:1585-600. doi:10.1084/jem.20140484
60. Ben Youssef G, Tourret M, Salou M, Ghazarian L, Houdouin V, Mondot S, et al. Ontogeny of human mucosal-associated invariant T cells and related T cell subsets. J Exp Med (2018) 215:459-79. doi:10.1084/jem.20171739
61. Gherardin NA, Keller AN, Woolley RE, Le Nours J, Ritchie DS, Neeson PJ, et al. Diversity of T cells restricted by the MHC class I-related molecule MR1 facilitates differential antigen recognition. Immunity (2016) 44:32-45. doi:10.1016/j.immuni.2015.12.005
62. Lepore M, Kalinichenko A, Calogero S, Kumar P, Paleja B, Schmaler M, et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. Elife (2017) 6:ii:e24476. doi:10.7554/eLife.24476
63. Meermeier EW, Laugel BF, Sewell AK, Corbett AJ, Rossjohn J, McCluskey J, et al. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat Commun (2016) 7:12506. doi:10.1038/ncomms12506
64. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 491:717-23. doi:10.1038/nature11605
65. Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature (2014) 509:361-5. doi:10.1038/nature13160
66. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, et al. In vitro and in vivo analysis of the Gram-negative bacteria-derived riboflavin precursor derivatives activating mouse MAIT cells. J Immunol (2015) 194:4641-9. doi:10.4049/jimmunol.1403224
67. Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SBG, Meehan B, et al. Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. J Exp Med (2015) 212:1095-108. doi:10.1084/jem.20142110
68. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. Proc Natl Acad Sci U S A (2016) 113:10133-8. doi:10.1073/pnas.1610750113
69. Le Bourhis L, Martin E, Péguillet I, Guihot A, Froux N, Coré M, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol (2010) 11:701-8. doi:10.1038/ni.1890
70. Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1-and MR1-restricted T cells. Annu Rev Immunol (2014) 32:323-66. doi:10.1146/annurev-immunol-032713-120243
71. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol (2010) 8:e1000407. doi:10.1371/journal.pbio.1000407
72. Lepore M, Kalinichenko A, Kalinicenko A, Colone A, Paleja B, Singhal A, et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire. Nat Commun (2014) 5:3866. doi:10.1038/ncomms4866
73. Kawachi I, Maldonado J, Strader C, Gilfillan S. MR1-restricted V alpha 19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. J Immunol (2006) 176:1618-27. doi:10.4049/jimmunol.176.3.1618
74. Cui Y, Franciszkiewicz K, Mburu YK, Mondot S, Le Bourhis L, Premel V, et al. Mucosal-associated invariant T cell-rich congenic mouse strain allows functional evaluation. J Clin Invest (2015) 125:4171-85. doi:10.1172/JCI82424
75. van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, et al. MAIT cells are activated during human viral infections. Nat Commun (2016) 7:11653. doi:10.1038/ncomms11653
76. Paquin-Proulx D, Avelino-Silva VI, Santos BAN, Silveira Barsotti N, Siroma F, Fernandes Ramos J, et al. MAIT cells are activated in acute dengue virus infection and after in vitro Zika virus infection. PLoS Negl Trop Dis (2018) 12:e0006154. doi:10.1371/journal.pntd.0006154
77. Fernandez CS, Amarasena T, Kelleher AD, Rossjohn J, McCluskey J, Godfrey DI, et al. MAIT cells are depleted early but retain functional cytokine expression in HIV infection. Immunol Cell Biol (2015) 93:177-88. doi:10.1038/icb.2014.91
78. Leeansyah E, Svärd J, Dias J, Buggert M, Nyström J, Quigley MF, et al. Arming of MAIT cell cytolytic antimicrobial activity is induced by IL-7 and defective in HIV-1 infection. PLoS Pathog (2015) 11:e1005072. doi:10.1371/journal.ppat.1005072
79. Sundström P, Ahlmanner F, Akéus P, Sundquist M, Alsén S, Yrlid U, et al. Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-γ. J Immunol (2015) 195:3472-81. doi:10.4049/jimmunol.1500258
80. Won EJ, Ju JK, Cho Y-N, Jin H-M, Park K-J, Kim T-J, et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget (2016) 7:76274-90. doi:10.18632/oncotarget.11187
81. Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A, et al. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Sci Rep (2018) 8:4159. doi:10.1038/s41598-018-22130-1
82. Zabijak L, Attencourt C, Guignant C, Chatelain D, Marcelo P, Marolleau J-P, et al. Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. Cancer Immunol Immunother (2015) 64:1601-8. doi:10.1007/s00262-015-1764-7
83. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest (2015) 125:1752-62. doi:10.1172/JCI78941
84. Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L, et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat Immunol (2017) 18:1321-31. doi:10.1038/ni.3854
85. Serriari N-E, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol (2014) 176:266-74. doi:10.1111/cei.12277
86. Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, Yasumi T, et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 21:1529-40. doi:10.1097/MIB.0000000000000397
87. Varelias A, Bunting MD, Ormerod KL, Koyama M, Olver SD, Straube J, et al. Recipient mucosal-associated invariant T cells control GVHD within the colon. J Clin Invest (2018) 128:1919-36. doi:10.1172/JCI91646
88. Kwon YS, Jin H-M, Cho Y-N, Kim M-J, Kang J-H, Jung H-J, et al. Mucosal-associated invariant T cell deficiency in chronic obstructive pulmonary disease. COPD (2016) 13:196-202. doi:10.3109/15412555.2015.1069806
89. Szabó M, Sárosi V, Balikó Z, Bodó K, Farkas N, Berki T, et al. Deficiency of innate-like T lymphocytes in chronic obstructive pulmonary disease. Respir Res (2017) 18:197. doi:10.1186/s12931-017-0671-1
90. Salou M, Nicol B, Garcia A, Baron D, Michel L, Elong-Ngono A, et al. Neuropathologic, phenotypic and functional analyses of mucosal associated invariant T cells in multiple sclerosis. Clin Immunol (2016) 166-167:1-11. doi:10.1016/j.clim.2016.03.014
91. Willing A, Jäger J, Reinhardt S, Kursawe N, Friese MA. Production of IL-17 by MAIT cells is increased in multiple sclerosis and is associated with IL-7 receptor expression. J Immunol (2018) 200:974-82. doi:10.4049/jimmunol.1701213
92. Thanabalasuriar A, Neupane AS, Wang J, Krummel MF, Kubes P. iNKT cell emigration out of the lung vasculature requires neutrophils and monocyte-derived dendritic cells in inflammation. Cell Rep (2016) 16:3260-72. doi:10.1016/j.celrep.2016.07.052
93. Scanlon ST, Thomas SY, Ferreira CM, Bai L, Krausz T, Savage PB, et al. Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. J Exp Med (2011) 208:2113-24. doi:10.1084/jem.20110522
94. Lee YJ, Wang H, Starrett GJ, Phuong V, Jameson SC, Hogquist KA. Tissue-specific distribution of iNKT cells impacts their cytokine response. Immunity (2015) 43:566-78. doi:10.1016/j.immuni.2015.06.025
95. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science (2012) 336:489-93. doi:10.1126/science.1219328
96. Dieli F, Taniguchi M, Kronenberg M, Sidobre S, Ivanyi J, Fattorini L, et al. An anti-inflammatory role for V alpha 14 NK T cells in Mycobacterium bovis bacillus Calmette-Guérin-infected mice. J Immunol (2003) 171:1961-8. doi:10.4049/jimmunol.171.4.1961
97. Kawakami K, Kinjo Y, Uezu K, Miyagi K, Kinjo T, Yara S, et al. Interferon-gamma production and host protective response against Mycobacterium tuberculosis in mice lacking both IL-12p40 and IL-18. Microbes Infect (2004) 6:339-49. doi:10.1016/j.micinf.2004.01.003
98. Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guérin. Eur J Immunol (1999) 29:650-9. doi:10.1002/(SICI)1521-4141(199902)29:02<650::AID-IMMU650>3.0.CO;2-M
99. Chiba A, Dascher CC, Besra GS, Brenner MB. Rapid NKT cell responses are self-terminating during the course of microbial infection. J Immunol (2008) 181:2292-302. doi:10.4049/jimmunol.181.4.2292
100. Sugawara I, Yamada H, Mizuno S, Li CY, Nakayama T, Taniguchi M. Mycobacterial infection in natural killer T cell knockout mice. Tuberculosis (Edinb) (2002) 82:97-104. doi:10.1054/tube.2002.0331
101. Kawakami K, Kinjo Y, Uezu K, Yara S, Miyagi K, Koguchi Y, et al. Minimal contribution of Valpha14 natural killer T cells to Th1 response and host resistance against mycobacterial infection in mice. Microbiol Immunol (2002) 46:207-10. doi:10.1111/j.1348-0421.2002.tb02687.x
102. Sköld M, Behar SM. Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun (2003) 71:5447-55. doi:10.1128/IAI.71.10.5447-5455.2003
103. Sousa AO, Mazzaccaro RJ, Russell RG, Lee FK, Turner OC, Hong S, et al. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci U S A (2000) 97:4204-8. doi:10.1073/pnas.97.8.4204
104. Szalay G, Zügel U, Ladel CH, Kaufmann SH. Participation of group 2 CD1 molecules in the control of murine tuberculosis. Microbes Infect (1999) 1:1153-7. doi:10.1016/S1286-4579(99)00248-8
105. Apostolou I, Takahama Y, Belmant C, Kawano T, Huerre M, Marchal G, et al. Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci U S A (1999) 96:5141-6. doi:10.1073/pnas.96.9.5141
106. Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med (1999) 189:1973-80. doi:10.1084/jem.189.12.1973
107. Chua W-J, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun (2012) 80:3256-67. doi:10.1128/IAI.00279-12
108. Hill TM, Gilchuk P, Cicek BB, Osina MA, Boyd KL, Durrant DM, et al. Border patrol gone awry: lung NKT cell activation by Francisella tularensis exacerbates tularemia-like disease. PLoS Pathog (2015) 11:e1004975. doi:10.1371/journal.ppat.1004975
109. Meierovics A, Yankelevich W-JC, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci U S A (2013) 110:E3119-28. doi:10.1073/pnas.1302799110
110. Meierovics AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. J Exp Med (2016) 213:2793-809. doi:10.1084/jem.20160637
111. Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, Uezu K, et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol (2003) 33:3322-30. doi:10.1002/eji.200324254
112. Barthelemy A, Ivanov S, Fontaine J, Soulard D, Bouabe H, Paget C, et al. Influenza A virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection. Mucosal Immunol (2017) 10:460-9. doi:10.1038/mi.2016.49
113. Nakamatsu M, Yamamoto N, Hatta M, Nakasone C, Kinjo T, Miyagi K, et al. Role of interferon-gamma in Valpha14+ natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect (2007) 9:364-74. doi:10.1016/j.micinf.2006.12.003
114. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 12:966-74. doi:10.1038/ni.2096
115. King IL, Amiel E, Tighe M, Mohrs K, Veerapen N, Besra G, et al. The mechanism of splenic invariant NKT cell activation dictates localization in vivo. J Immunol (2013) 191:572-82. doi:10.4049/jimmunol.1300299
116. Hartmann N, McMurtrey C, Sorensen ML, Huber ME, Kurapova R, Coleman FT, et al. Riboflavin metabolism variation among clinical isolates of Streptococcus pneumoniae results in differential activation of MAIT cells. Am J Respir Cell Mol Biol (2018) 58(6):767-76. doi:10.1165/rcmb.2017-0290OC
117. Kok WL, Denney L, Benam K, Cole S, Clelland C, McMichael AJ, et al. Pivotal advance: invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection. J Leukoc Biol (2012) 91:357-68. doi:10.1189/jlb.0411184
118. Paget C, Ivanov S, Fontaine J, Blanc F, Pichavant M, Renneson J, et al. Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. J Immunol (2011) 186:5590-602. doi:10.4049/jimmunol.1002348
119. De Santo C, Salio M, Masri SH, Lee LY-H, Dong T, Speak AO, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 118:4036-48. doi:10.1172/JCI36264
120. Paget C, Ivanov S, Fontaine J, Renneson J, Blanc F, Pichavant M, et al. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J Biol Chem (2012) 287:8816-29. doi:10.1074/jbc.M111.304758
121. Organization WH. Global Tuberculosis Report 2015. World Health Organization (2015). Available from: http://apps.who.int/iris/handle/10665/191102 (Accessed: May 17, 2018)
122. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med (2016) 13:e1002152. doi:10.1371/journal.pmed.1002152
123. Getahun H, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 373:1179-80. doi:10.1056/NEJMc1508223
124. Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med (1931) 24:1481-90
125. Global Tuberculosis Report 2014. (2015). Available from: http://apps.who.int/medicinedocs/en/d/Js21634en/ (Accessed: May 17, 2018)
126. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog (2008) 4:e1000239. doi:10.1371/journal.ppat.1000239
127. Rothchild AC, Jayaraman P, Nunes-Alves C, Behar SM. iNKT cell production of GM-CSF controls Mycobacterium tuberculosis. PLoS Pathog (2014) 10:e1003805. doi:10.1371/journal.ppat.1003805
128. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci U S A (2004) 101:10685-90. doi:10.1073/pnas.0403787101
129. Montoya CJ, Cataño JC, Ramirez Z, Rugeles MT, Wilson SB, Landay AL. Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol (2008) 127:1-6. doi:10.1016/j.clim.2007.12.006
130. Snyder-Cappione JE, Nixon DF, Loo CP, Chapman JM, Meiklejohn DA, Melo FF, et al. Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J Infect Dis (2007) 195:1361-4. doi:10.1086/513567
131. Sutherland JS, Jeffries DJ, Donkor S, Walther B, Hill PC, Adetifa IMO, et al. High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. Tuberculosis (Edinb) (2009) 89:398-404. doi:10.1016/j.tube.2009.07.004
132. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 11:131-42. doi:10.1038/nri2904
133. Im JS, Kang T-J, Lee S-B, Kim C-H, Lee S-H, Venkataswamy MM, et al. Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. Clin Immunol (2008) 127:214-24. doi:10.1016/j.clim.2007.12.005
134. Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N, et al. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol (2006) 145:252-60. doi:10.1111/j.1365-2249.2006.03144.x
135. Li Z, Yang B, Zhang Y, Ma J, Chen X, Lao S, et al. Mycobacterium tuberculosis-specific memory NKT cells in patients with tuberculous pleurisy. J Clin Immunol (2014) 34:979-90. doi:10.1007/s10875-014-0090-8
136. Singh A, Dey AB, Mohan A, Mitra DK. Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis. Tuberculosis (Edinb) (2014) 94:197-206. doi:10.1016/j.tube.2014.01.005
137. Kee S-J, Kwon Y-S, Park Y-W, Cho Y-N, Lee S-J, Kim T-J, et al. Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection. Infect Immun (2012) 80:2100-8. doi:10.1128/IAI.06018-11
138. Wu C, Li Z, Fu X, Yu S, Lao S, Yang B. Antigen-specific human NKT cells from tuberculosis patients produce IL-21 to help B cells for the production of immunoglobulins. Oncotarget (2015) 6:28633-45. doi:10.18632/oncotarget.5764
139. Sada-Ovalle I, Sköld M, Tian T, Besra GS, Behar SM. Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med (2010) 182:841-7. doi:10.1164/rccm.200912-1921OC
140. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun (2002) 70:6302-9. doi:10.1128/IAI.70.11.6302-6309.2002
141. Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, Chan J, et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol (2009) 183:1644-56. doi:10.4049/jimmunol.0900858
142. Khan A, Singh S, Galvan G, Jagannath C, Sastry KJ. Prophylactic sublingual immunization with mycobacterium tuberculosis subunit vaccine incorporating the natural killer T cell agonist alpha-galactosylceramide enhances protective immunity to limit pulmonary and extra-pulmonary bacterial burden in mice. Vaccines (Basel) (2017) 5:47-59. doi:10.3390/vaccines5040047
143. Cavallo GP, Elia M, Giordano D, Baldi C, Cammarota R. Decrease of specific and total IgE levels in allergic patients after BCG vaccination: preliminary report. Arch Otolaryngol Head Neck Surg (2002) 128:1058-60. doi:10.1001/archotol.128.9.1058
144. Herz U, Gerhold K, Grüber C, Braun A, Wahn U, Renz H, et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol (1998) 102:867-74. doi:10.1016/S0091-6749(98)70030-2
145. Harada M, Magara-Koyanagi K, Watarai H, Nagata Y, Ishii Y, Kojo S, et al. IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses. J Exp Med (2006) 203:2929-37. doi:10.1084/jem.20062206
146. Kwon Y-S, Cho Y-N, Kim M-J, Jin H-M, Jung H-J, Kang J-H, et al. Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. Tuberculosis (Edinb) (2015) 95:267-74. doi:10.1016/j.tube.2015.03.004
147. Jiang J, Wang X, An H, Yang B, Cao Z, Liu Y, et al. Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis. Am J Respir Crit Care Med (2014) 190:329-39. doi:10.1164/rccm.201401-0106OC
148. Gold MC, Eid T, Smyk-Pearson S, Eberling Y, Swarbrick GM, Langley SM, et al. Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. Mucosal Immunol (2013) 6:35-44. doi:10.1038/mi.2012.45
149. Harriff MJ, Cansler ME, Toren KG, Canfield ET, Kwak S, Gold MC, et al. Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8+ T cells. PLoS One (2014) 9:e97515. doi:10.1371/journal.pone.0097515
150. Oyston PCF. Francisella tularensis: unravelling the secrets of an intracellular pathogen. J Med Microbiol (2008) 57:921-30. doi:10.1099/jmm.0.2008/000653-0
151. Ellis J, Oyston PCF, Green M, Titball RW. Tularemia. Clin Microbiol Rev (2002) 15:631-46. doi:10.1128/CMR.15.4.631-646.2002
152. Keim P, Johansson A, Wagner DM. Molecular epidemiology, evolution, and ecology of Francisella. Ann N Y Acad Sci (2007) 1105:30-66. doi:10.1196/annals.1409.011
153. McLendon MK, Apicella MA, Allen L-AH. Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol (2006) 60:167-85. doi:10.1146/annurev.micro.60.080805.142126
154. Sharma J, Li Q, Mishra BB, Pena C, Teale JM. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J Leukoc Biol (2009) 86:491-504. doi:10.1189/jlb.1208728
155. Bendelac A, Hunziker RD, Lantz O. Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J Exp Med (1996) 184:1285-93. doi:10.1084/jem.184.4.1285
156. Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL. Lung CD4-CD8-double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol (2010) 184:5791-801. doi:10.4049/jimmunol.1000362
157. Jesteadt E, Zhang I, Yu H, Meierovics A, Chua Yankelevich W-J, Cowley S. Interleukin-18 is critical for mucosa-associated invariant T cell gamma interferon responses to Francisella species in vitro but not in vivo. Infect Immun (2018) 86:e00117-18. doi:10.1128/IAI.00117-18
158. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol (2018) 16:355-67. doi:10.1038/s41579-018-0001-8
159. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with Influenza Pandemics. Front Microbiol (2017) 8:1041. doi:10.3389/fmicb.2017.01041
160. Domenech A, Ardanuy C, Tercero A, García-Somoza D, Santos S, Liñares J. Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods. J Antimicrob Chemother (2014) 69:932-9. doi:10.1093/jac/dkt476
161. Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother (2016) 12:383-92. doi:10.1080/21645515.2015.1087625
162. Bröker M, Berti F, Schneider J, Vojtek I. Polysaccharide conjugate vaccine protein carriers as a 'neglected valency'-potential and limitations. Vaccine (2017) 35:3286-94. doi:10.1016/j.vaccine.2017.04.078
163. Cherazard R, Epstein M, Doan T-L, Salim T, Bharti S, Smith MA. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther (2017) 24:e361-9. doi:10.1097/MJT.0000000000000551
164. Ivanov S, Fontaine J, Paget C, Macho Fernandez E, Van Maele L, Renneson J, et al. Key role for respiratory CD103(+) dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide. J Infect Dis (2012) 206:723-34. doi:10.1093/infdis/jis413
165. Shimamura M, Yamamura M, Nabeshima T, Kitano N, van den Elzen P, Yesilkaya H, et al. Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids. Sci Rep (2017) 7:9703. doi:10.1038/s41598-017-10309-x
166. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, Pillai S, et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A (2008) 105:8339-44. doi:10.1073/pnas.0801375105
167. Miyasaka T, Akahori Y, Toyama M, Miyamura N, Ishii K, Saijo S, et al. Dectin-2-dependent NKT cell activation and serotype-specific antibody production in mice immunized with pneumococcal polysaccharide vaccine. PLoS One (2013) 8:e78611. doi:10.1371/journal.pone.0078611
168. Kobrynski LJ, Sousa AO, Nahmias AJ, Lee FK. Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. J Immunol (2005) 174:1787-90. doi:10.4049/jimmunol.174.4.1787
169. Bai L, Deng S, Reboulet R, Mathew R, Teyton L, Savage PB, et al. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A (2013) 110:16097-102. doi:10.1073/pnas.1303218110
170. Deng S, Bai L, Reboulet R, Matthew R, Engler DA, Teyton L, et al. A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses in vivo. Chem Sci (2014) 5:1437-41. doi:10.1039/C3SC53471E
171. Thorburn AN, O'Sullivan BJ, Thomas R, Kumar RK, Foster PS, Gibson PG, et al. Pneumococcal conjugate vaccine-induced regulatory T cells suppress the development of allergic airways disease. Thorax (2010) 65:1053-60. doi:10.1136/thx.2009.131508
172. Preston JA, Thorburn AN, Starkey MR, Beckett EL, Horvat JC, Wade MA, et al. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur Respir J (2011) 37:53-64. doi:10.1183/09031936.00049510
173. Preston JA, Essilfie A-T, Horvat JC, Wade MA, Beagley KW, Gibson PG, et al. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine (2007) 25:8154-62. doi:10.1016/j.vaccine.2007.09.034
174. Thorburn AN, Foster PS, Gibson PG, Hansbro PM. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol (2012) 188:4611-20. doi:10.4049/jimmunol.1101299
175. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science (2001) 293:498-506. doi:10.1126/science.1061217
176. Lanie JA, Ng W-L, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ, et al. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol (2007) 189:38-51. doi:10.1128/JB.01148-06
177. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL, et al. Diverse Streptococcus pneumoniae strains drive a mucosal-associated invariant T-cell response through major histocompatibility complex class I-related molecule-dependent and cytokine-driven pathways. J Infect Dis (2018) 217:988-99. doi:10.1093/infdis/jix647
178. Hassane M, Demon D, Soulard D, Fontaine J, Keller LE, Patin EC, et al. Neutrophilic NLRP3 inflammasome-dependent IL-1β secretion regulates the γδT17 cell response in respiratory bacterial infections. Mucosal Immunol (2017) 10:1056-68. doi:10.1038/mi.2016.113
179. Cao J, Wang D, Xu F, Gong Y, Wang H, Song Z, et al. Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol Med (2014) 6:120-40. doi:10.1002/emmm.201302890
180. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaaz F, et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med (2014) 40:192-201. doi:10.1007/s00134-013-3163-x
181. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol (2014) 14:315-28. doi:10.1038/nri3665
182. Monto AS. Epidemiology of influenza. Vaccine (2008) 26(Suppl 4):D45-8. doi:10.1016/j.vaccine.2008.07.066
183. Palese P. Influenza: old and new threats. Nat Med (2004) 10:S82-7. doi:10.1038/nm1141
184. McDonald SM, Nelson MI, Turner PE, Patton JT. Reassortment in segmented RNA viruses: mechanisms and outcomes. Nat Rev Microbiol (2016) 14:448-60. doi:10.1038/nrmicro.2016.46
185. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol (2018) 16:47-60. doi:10.1038/nrmicro.2017.118
186. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol (2014) 12:252-62. doi:10.1038/nrmicro3231
187. Ballinger MN, Standiford TJ. Postinfluenza bacterial pneumonia: host defenses gone awry. J Interferon Cytokine Res (2010) 30:643-52. doi:10.1089/jir.2010.0049
188. Short KR, Kroeze EJBV, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis (2014) 14:57-69. doi:10.1016/S1473-3099(13)70286-X
189. Abdul-Careem MF, Mian MF, Yue G, Gillgrass A, Chenoweth MJ, Barra NG, et al. Critical role of natural killer cells in lung immunopathology during influenza infection in mice. J Infect Dis (2012) 206:167-77. doi:10.1093/infdis/jis340
190. Aldridge JR, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, Franks J, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A (2009) 106:5306-11. doi:10.1073/pnas.0900655106
191. Ivanov S, Renneson J, Fontaine J, Barthelemy A, Paget C, Fernandez EM, et al. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. J Virol (2013) 87:6911-24. doi:10.1128/JVI.02943-12
192. Pociask DA, Scheller EV, Mandalapu S, McHugh KJ, Enelow RI, Fattman CL, et al. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol (2013) 182:1286-96. doi:10.1016/j.ajpath.2012.12.007
193. Barthelemy A, Sencio V, Soulard D, Deruyter L, Faveeuw C, Le Goffic R, et al. Interleukin-22 immunotherapy during severe influenza enhances lung tissue integrity and reduces secondary bacterial systemic invasion. Infect Immun (2018) 86(7):e706-17. doi:10.1128/IAI.00706-17
194. Barthelemy A, Ivanov S, Hassane M, Fontaine J, Heurtault B, Frisch B, et al. Exogenous activation of invariant natural killer T cells by α-galactosylceramide reduces pneumococcal outgrowth and dissemination postinfluenza. MBio (2016) 7:e1440-1416. doi:10.1128/mBio.01440-16
195. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol (2014) 44:195-203. doi:10.1002/eji.201343509
196. Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8a+ semi-invariant T cells. Blood (2011) 118:2752-62. doi:10.1182/blood-2011-02-334698
197. Gleimer M, von Boehmer H, Kreslavsky T. PLZF controls the expression of a limited number of genes essential for NKT cell function. Front Immunol (2012) 3:374. doi:10.3389/fimmu.2012.00374
198. Paget C, Trottein F. Role of type 1 natural killer T cells in pulmonary immunity. Mucosal Immunol (2013) 6:1054-67. doi:10.1038/mi.2013.59
199. Scheuplein F, Lamont DJ, Poynter ME, Boyson JE, Serreze D, Lundblad LKA, et al. Mouse invariant monoclonal antibody NKT14: a novel tool to manipulate iNKT cell function in vivo. PLoS One (2015) 10:e0140729. doi:10.1371/journal.pone.0140729
200. Godfrey DI, Le Nours J, Andrews DM, Uldrich AP, Rossjohn J. Unconventional T cell targets for cancer immunotherapy. Immunity (2018) 48:453-73. doi:10.1016/j.immuni.2018.03.009
201. Bedard M, Salio M, Cerundolo V. Harnessing the power of invariant natural killer T cells in cancer immunotherapy. Front Immunol (2017) 8:1829. doi:10.3389/fimmu.2017.01829
202. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol (2009) 9:28-38. doi:10.1038/nri2451
203. Mak JYW, Xu W, Reid RC, Corbett AJ, Meehan BS, Wang H, et al. Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. Nat Commun (2017) 8:14599. doi:10.1038/ncomms14599
204. Li K, Vorkas CK, Chaudhry A, Bell DL, Willis RA, Rudensky A, et al. Synthesis, stabilization, and characterization of the MR1 ligand precursor 5-amino-6-D-ribitylaminouracil (5-A-RU). PLoS One (2018) 13:e0191837. doi:10.1371/journal.pone.0191837
205. Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, et al. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell (2013) 12:546-58. doi:10.1016/j.stem.2013.03.001
206. Sheridan C. Allogene and celularity move CAR-T therapy off the shelf. Nat Biotechnol (2018) 36:375-7. doi:10.1038/nbt0518-375
207. Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood (2014) 124:2824-33. doi:10.1182/blood-2013-11-541235
208. Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, et al. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest (2016) 126:2341-55. doi:10.1172/JCI83476
209. Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol (2018) 18:91-104. doi:10.1038/nri.2017.112
210. Brown KE, Freeman GJ, Wherry EJ, Sharpe AH. Role of PD-1 in regulating acute infections. Curr Opin Immunol (2010) 22:397-401. doi:10.1016/j.coi.2010.03.007
211. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol (2018) 18:153-67. doi:10.1038/nri.2017.108
212. Patil NK, Guo Y, Luan L, Sherwood ER. Targeting immune cell checkpoints during sepsis. Int J Mol Sci (2017) 18:2413. doi:10.3390/ijms18112413
213. Biburger M, Tiegs G. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors. J Leukoc Biol (2008) 84:264-79. doi:10.1189/jlb.0607352
214. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang C-R, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest (2005) 115:2572-83. doi:10.1172/JCI24762
215. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med (2005) 201:1503-17. doi:10.1084/jem.20042592
216. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol (2002) 3:867-74. doi:10.1038/ni827
217. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, et al. Targeted delivery of α-galactosylceramide to CD8a+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol (2014) 193:961-9. doi:10.4049/jimmunol.1303029
218. Ghinnagow R, De Meester J, Cruz LJ, Aspord C, Corgnac S, Macho-Fernandez E, et al. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. Oncoimmunology (2017) 6:e1339855. doi:10.1080/2162402X.2017.1339855